WEBVTT - Commissioner of the Food and Drug Administration Dr. Marty Makary Talks Psychedelics

0:00:02.520 --> 0:00:22.079
<v Speaker 1>Bloomberg Audio studios, podcasts, radio news.

0:00:14.440 --> 0:00:17.880
<v Speaker 2>Stocks tied to psychedelic therapeutics jumping today in a big

0:00:17.920 --> 0:00:21.320
<v Speaker 2>way after President Donald Trump's executive order aimed at faster

0:00:21.480 --> 0:00:25.120
<v Speaker 2>research and access to once taboo treatments. The new order

0:00:25.160 --> 0:00:28.520
<v Speaker 2>directs the FDA to lean on a so called breakthrough

0:00:28.640 --> 0:00:33.040
<v Speaker 2>designation to cut down their review times to one to

0:00:33.159 --> 0:00:36.479
<v Speaker 2>two months. Previously that was six to ten months. I'm

0:00:36.520 --> 0:00:38.440
<v Speaker 2>pleased to say that we're joined live now by FDA

0:00:38.479 --> 0:00:41.680
<v Speaker 2>Commissioner Marty McCarey. Great to have you with us, and

0:00:41.720 --> 0:00:44.599
<v Speaker 2>I do want to talk about you know, why this research,

0:00:44.720 --> 0:00:47.640
<v Speaker 2>Why prioritize it now, because I mean some of the

0:00:47.680 --> 0:00:50.879
<v Speaker 2>issues that we're talking about, these are things that have

0:00:50.880 --> 0:00:53.960
<v Speaker 2>been discussed for years. So bring us to this moment.

0:00:55.200 --> 0:00:58.400
<v Speaker 3>Well, this is a historic moment in American medicine. Fifty

0:00:58.440 --> 0:01:00.680
<v Speaker 3>million dollars is going to be allocated into this type

0:01:00.680 --> 0:01:04.080
<v Speaker 3>of research. We've seen some preliminary data that is promising.

0:01:04.560 --> 0:01:08.200
<v Speaker 3>That is remission rates of thirty to forty percent for

0:01:08.319 --> 0:01:12.440
<v Speaker 3>PTSD conditions where there's otherwise no good treatment. We've also

0:01:12.480 --> 0:01:17.920
<v Speaker 3>heard dramatic stories of veterans having a profound benefit, and

0:01:17.959 --> 0:01:20.880
<v Speaker 3>those individual stories are a form of data too, that

0:01:21.000 --> 0:01:23.600
<v Speaker 3>is scientific data. We just need to see all of

0:01:23.600 --> 0:01:27.679
<v Speaker 3>it together and assure safety and efficacy. The applications around

0:01:27.720 --> 0:01:30.240
<v Speaker 3>these products are now getting to the point where they're

0:01:30.280 --> 0:01:34.760
<v Speaker 3>mature enough where the applications are about to arrive here

0:01:34.800 --> 0:01:38.280
<v Speaker 3>at the FDA, So we are issuing three National Priority

0:01:38.319 --> 0:01:40.479
<v Speaker 3>vouchers to get a decision out in one to two

0:01:40.480 --> 0:01:43.120
<v Speaker 3>months instead of the typical year, in addition to the

0:01:43.160 --> 0:01:46.240
<v Speaker 3>research funding and a new pathway so that it will

0:01:46.280 --> 0:01:48.760
<v Speaker 3>not be considered a controlled substance at the time of

0:01:48.800 --> 0:01:53.440
<v Speaker 3>administration in a controlled medical setting. I think this has

0:01:53.480 --> 0:01:55.520
<v Speaker 3>been an issue where for a long time there's been

0:01:55.560 --> 0:01:58.200
<v Speaker 3>some good preliminary data. We now have to take a

0:01:58.200 --> 0:02:00.680
<v Speaker 3>hard look at that data, and for those suffering with

0:02:00.760 --> 0:02:04.480
<v Speaker 3>PTSD and other debilitating addictions, we owe it to them

0:02:04.520 --> 0:02:06.120
<v Speaker 3>to get those decisions out quickly.

0:02:06.840 --> 0:02:09.160
<v Speaker 2>And so there's a lot of focus here on ibogain,

0:02:09.240 --> 0:02:12.160
<v Speaker 2>which is I understand it is a psychedelic compound that's

0:02:12.480 --> 0:02:15.960
<v Speaker 2>extracted from an African plant. And when it comes to

0:02:16.800 --> 0:02:19.560
<v Speaker 2>the FDA that new guidance that you were directed to

0:02:19.560 --> 0:02:24.120
<v Speaker 2>give to researchers to study ibogain, do you expect that

0:02:24.440 --> 0:02:28.920
<v Speaker 2>the US is going to reclassify ibogain and other psychedelic

0:02:29.000 --> 0:02:33.040
<v Speaker 2>controlled substances to make it easier to study them. And

0:02:33.240 --> 0:02:35.359
<v Speaker 2>if so, is there any sort of timeline you can give.

0:02:35.280 --> 0:02:38.840
<v Speaker 3>Us, Well, not only do we allocate funding to study

0:02:39.080 --> 0:02:42.960
<v Speaker 3>drugs like ibogain, but also created a pathway so that

0:02:43.120 --> 0:02:48.040
<v Speaker 3>normally when there's an FDA approval, there's a temporary rescheduling

0:02:48.080 --> 0:02:50.800
<v Speaker 3>to enable clinicians to use it. That we have that

0:02:50.919 --> 0:02:53.200
<v Speaker 3>with fentanyl and a number of drugs that are used

0:02:53.480 --> 0:02:56.280
<v Speaker 3>in the operating room in America every day. So that

0:02:56.440 --> 0:02:59.160
<v Speaker 3>is our normal process. We want it to be expeditious.

0:02:59.200 --> 0:03:02.560
<v Speaker 3>We don't want red tape to slow this down, and

0:03:02.639 --> 0:03:08.639
<v Speaker 3>that's because the stories that we're hearing are pretty amazing stories.

0:03:08.680 --> 0:03:11.840
<v Speaker 3>Now we need to do the proper phase three clinical

0:03:11.840 --> 0:03:15.840
<v Speaker 3>trials because if we recommend these treatments as a physician

0:03:15.880 --> 0:03:19.320
<v Speaker 3>community to patients, they want to know what the numbers are.

0:03:19.400 --> 0:03:22.880
<v Speaker 3>There are side effects, people have died from these medications.

0:03:23.520 --> 0:03:26.840
<v Speaker 3>But on Saturday, with President Trump, I did announce the

0:03:26.880 --> 0:03:31.960
<v Speaker 3>first ever clearance of an Investigational new drug registration for

0:03:32.280 --> 0:03:35.040
<v Speaker 3>nor i BEGAIN, a form of i BEGAIN for first

0:03:35.040 --> 0:03:37.880
<v Speaker 3>in human trials that'll pave the way for the proper

0:03:37.920 --> 0:03:39.440
<v Speaker 3>clinical studies to be done.

0:03:39.680 --> 0:03:41.560
<v Speaker 4>I am curious about some of the studies that have

0:03:41.640 --> 0:03:44.160
<v Speaker 4>already been done on some of these compounds. Of course,

0:03:44.160 --> 0:03:46.040
<v Speaker 4>there was a lot of controversy a few years ago

0:03:46.520 --> 0:03:49.000
<v Speaker 4>when the FDA rejected I think was an application for

0:03:49.360 --> 0:03:53.160
<v Speaker 4>basically MDMA or what we would call MDMA, and the

0:03:53.240 --> 0:03:57.120
<v Speaker 4>idea there was that despite whatever evidence the trials showed

0:03:57.160 --> 0:04:01.960
<v Speaker 4>about the benefit, there was some concern about safety. What's

0:04:02.040 --> 0:04:05.400
<v Speaker 4>changed since that rejection in twenty twenty four and where

0:04:05.400 --> 0:04:06.279
<v Speaker 4>we are today.

0:04:07.160 --> 0:04:09.720
<v Speaker 3>Well, that company has gone back and done an audit.

0:04:10.400 --> 0:04:13.320
<v Speaker 3>If that company submits the results of their audit for

0:04:13.400 --> 0:04:17.760
<v Speaker 3>the protocol violation that was cited in the rejection about

0:04:17.800 --> 0:04:20.760
<v Speaker 3>two years ago before I was leading the FDA, then

0:04:20.800 --> 0:04:25.560
<v Speaker 3>that'll be considered in due process. But there are side

0:04:25.560 --> 0:04:31.239
<v Speaker 3>effects that require that there are conditions that are strictly

0:04:31.240 --> 0:04:35.080
<v Speaker 3>followed to administer these medications. For example, patients can become

0:04:35.360 --> 0:04:39.240
<v Speaker 3>highly amorous. There needs to be close supervision, not just

0:04:39.279 --> 0:04:42.080
<v Speaker 3>in a one on one setting, and we want to

0:04:42.120 --> 0:04:46.200
<v Speaker 3>make sure that there's adequate time to monitor patients if

0:04:46.240 --> 0:04:51.120
<v Speaker 3>they have cardiovascular complications which have been well described with

0:04:51.400 --> 0:04:54.040
<v Speaker 3>substances like I begain now. I began as the least

0:04:54.040 --> 0:04:56.960
<v Speaker 3>mature of all the studies that are done in the

0:04:57.040 --> 0:04:59.880
<v Speaker 3>United States. We have applications that are coming for other

0:05:00.200 --> 0:05:03.159
<v Speaker 3>psychedelics and they should be arriving this summer. Some of

0:05:03.160 --> 0:05:06.200
<v Speaker 3>those will get the priority voucher approval. But given the

0:05:07.400 --> 0:05:11.159
<v Speaker 3>degree of urgency around this problem, remember eighty nine percent

0:05:11.200 --> 0:05:14.760
<v Speaker 3>of vests with PTS are just getting antidepressants with SRSRIS,

0:05:15.200 --> 0:05:18.320
<v Speaker 3>it is very low effectiveness. It's not working well. We

0:05:18.400 --> 0:05:20.160
<v Speaker 3>can do better, so we owe it to them to

0:05:20.200 --> 0:05:21.400
<v Speaker 3>get decisions out quickly.

0:05:21.640 --> 0:05:23.479
<v Speaker 4>All Marty, I do before we let you go, I

0:05:23.480 --> 0:05:24.720
<v Speaker 4>do have to just ask you about some of the

0:05:24.920 --> 0:05:27.720
<v Speaker 4>other things going on at the FDA, particularly with regards

0:05:28.000 --> 0:05:30.840
<v Speaker 4>to the recent departure here of the head of the

0:05:30.920 --> 0:05:33.919
<v Speaker 4>vaccine program. Are you any closer to fining a replacement

0:05:33.960 --> 0:05:35.120
<v Speaker 4>for him?

0:05:35.760 --> 0:05:39.279
<v Speaker 3>Yeah, Well, the vaccine program lives within our Center for Biologics.

0:05:39.320 --> 0:05:42.000
<v Speaker 3>The head of the Center for Biologics was on a

0:05:42.000 --> 0:05:46.200
<v Speaker 3>sabbatical leave of absence from a university. He said at

0:05:46.240 --> 0:05:47.880
<v Speaker 3>the end of the month he will be going back

0:05:47.880 --> 0:05:50.560
<v Speaker 3>to the university. We have a lot of people who

0:05:50.560 --> 0:05:53.760
<v Speaker 3>are interested in that job. A very robust search, and

0:05:53.920 --> 0:05:57.880
<v Speaker 3>I expect an announcement soon. There are some outstanding candidates.

0:05:57.920 --> 0:05:59.600
<v Speaker 3>A lot of people want to work at the FDA.

0:06:00.040 --> 0:06:04.920
<v Speaker 3>We're hiring about three thousand scientists and inspectors at the FDA,

0:06:05.040 --> 0:06:07.640
<v Speaker 3>so we are growing and it's a great time to

0:06:07.680 --> 0:06:09.880
<v Speaker 3>be working at the FDA.

0:06:10.040 --> 0:06:12.200
<v Speaker 4>All right, Marty, really appreciate you taking time for US

0:06:12.279 --> 0:06:15.560
<v Speaker 4>FDA Commissioner Marty McKay there on the heels on that

0:06:15.600 --> 0:06:18.919
<v Speaker 4>executive order by the President of the United States Katie Gretfeld,

0:06:19.200 --> 0:06:23.080
<v Speaker 4>effectively paving the way potentially here for the first approval

0:06:23.640 --> 0:06:25.960
<v Speaker 4>of a psychedelic here in the United States. Yea.

0:06:25.960 --> 0:06:28.880
<v Speaker 2>And it's been fascinating to watch the reaction in these stocks.

0:06:28.920 --> 0:06:31.080
<v Speaker 2>I mean, for a lot of these companies, they're very,

0:06:31.240 --> 0:06:33.560
<v Speaker 2>very small. We're talking about some of the smallest of

0:06:33.680 --> 0:06:35.960
<v Speaker 2>small calves. But it's very similar to what we've seen

0:06:35.960 --> 0:06:38.760
<v Speaker 2>with marijuana stocks over the year. I mean, they just

0:06:39.000 --> 0:06:44.159
<v Speaker 2>trade over regulatory headlines and you know, it's a very

0:06:44.560 --> 0:06:47.200
<v Speaker 2>boom or bust, it feels like, and certainly, at least

0:06:47.240 --> 0:06:48.400
<v Speaker 2>for today, a boom.

0:06:48.640 --> 0:06:50.800
<v Speaker 4>Yeah, definitely a boom. We'll see how long it lasts.

0:06:50.800 --> 0:06:51.960
<v Speaker 4>And of course you have to get to the point

0:06:51.960 --> 0:06:54.400
<v Speaker 4>where you get through these trials and actually get some

0:06:54.400 --> 0:06:56.480
<v Speaker 4>sort of approval, And who is actually going to benefit

0:06:56.520 --> 0:06:56.760
<v Speaker 4>from that